News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
21
2025
-
04
Shanghai Suining Chamber of Commerce visited Kote Pharmaceutical & Linyi Pharmaceutical, exploring new opportunities for industrial cooperation!
Classification：
行业新闻
Corporate News
4 On August 18, Chairman Guo of the Shanghai Suining Chamber of Commerce led a delegation to visit and exchange with Koya Pharmaceutical (stock code: 301281.SZ) & Linoa Pharmaceutical Shanghai headquarters. Linoa Pharmaceutical executives, including Li Hongfu, warmly received the delegation. Both sides engaged in in-depth discussions on topics such as synergistic development of the pharmaceutical industry, technological innovation, and regional cooperation, outlining a broad blueprint for future in-depth cooperation.
The Suining Chamber of Commerce delegation first visited the group's digital innovation exhibition hall, giving high praise to the company's technological strength and development prospects. At the subsequent symposium, Li Hongfu, on behalf of Koya Pharmaceutical & Linoa Pharmaceutical, extended a warm welcome to Chairman Guo's delegation and gave a detailed introduction to the company's core products, current development status, and future plans.
Linoa Pharmaceutical is a subsidiary of Koya Pharmaceutical, focusing on the research, development, production, and sales of chemical drug formulations. Its products cover multiple therapeutic areas, including hypoglycemic, cardiovascular, and central nervous system drugs. In 2023, Koya Pharmaceutical and Linoa Pharmaceutical successfully listed on the Shenzhen Stock Exchange, further consolidating their competitive advantage in the industry.
“We have always adhered to a research and development-driven development strategy,” Li Hongfu emphasized. “The company has successively reached strategic cooperation with Beijing Nuokangda and holds a controlling stake in Hainan Linheng Pharmaceutical. These measures will significantly enhance our R&D capabilities and market competitiveness.” He also highlighted the company's core product lines, including its flagship products such as isosorbide mononitrate tablets and amiloride paste, as well as newly launched specialty drugs such as ambroxol hydrochloride drops.
The Shanghai Suining Chamber of Commerce delegation highly praised the development achievements of Koya Pharmaceutical & Linoa Pharmaceutical. Chairman Guo stated: “Suining, known as the ‘Pearl of Central Sichuan,’ has unique advantages in the biopharmaceutical field. We look forward to in-depth cooperation with innovative companies like Linoa Pharmaceutical to jointly promote the organic integration of ‘Suining Manufacturing’ and ‘Linoa Quality.’
The Shanghai Suining Chamber of Commerce, as an important bridge connecting the economies of Sichuan and Shanghai, has made significant contributions to promoting regional economic synergy over the years. This visit provided a good opportunity for in-depth cooperation between the two parties in various fields. Both sides will take this opportunity to fully leverage their respective advantages to explore more possibilities in pharmaceutical development, industrial chain synergy, talent and technology cooperation, and other areas, gradually realizing the beautiful vision of cross-regional cooperation.
Last article
Related news
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China
